Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Apr 2015
biocartis
Joint bookrunner
€ 115 million
Initial public offering

Biocartis

Biocartis is an innovative commercial stage molecular diagnostics company providing next generation diagnostic solutions.

  • With an initial market cap of €450m, Biocartis' IPO on Euronext Brussels is the largest Life Sciences IPO on Euronext since 2005
  • Proceeds of the IPO will be used to support R&D and to strengthen sales & marketing capabilities
  • Kempen & Co acted as Joint Bookrunner in the offering with demand exceeding €650m
 

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer